6-Methyl-MDA
Psychoactive drug
From Wikipedia, the free encyclopedia
6-Methyl-MDA, also known as 6-methyl-3,4-methylenedioxyamphetamine is an entactogen and psychedelic drug of the amphetamine and MDxx families.[2] It was first synthesized in the late 1990s by a team including David E. Nichols at Purdue University while investigating derivatives of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-methylamphetamine (MDMA).[2]
- None
- Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar laws in other countries)
| Clinical data | |
|---|---|
| Routes of administration | Oral[1] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO2 |
| Molar mass | 193.246 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
6-Methyl-MDA has IC50 values of 783 nM, 28,300 nM, and 4,602 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine in rat synaptosomes.[2] In animal studies it substitutes for MBDB, MMAI, LSD, and 2,5-dimethoxy-4-iodoamphetamine (DOI), though not amphetamine, but only partially and at high doses.[2] Thus, while several-fold less potent than its analogues 2-methyl-MDA and 5-methyl-MDA, and approximately half as potent as MDA, 6-methyl-MDA is still significantly active.[2]
According to Daniel Trachsel and colleagues, 6-methyl-MDA is active at a dose of 160 mg orally and has a duration of 8 hours.[1]
6-Methyl-MDA is a controlled substance in Canada under phenethylamine blanket-ban language.[3]